Immuneering (IMRX) Interest & Investment Income (2020 - 2026)
Immuneering (IMRX) posted quarterly Interest & Investment Income of $1.4 million for Q1 2026, up 210.23% year-over-year from $438520.0 in Q1 2025, and down 26.9% quarter-over-quarter from $1.9 million in Q4 2025.
Immuneering (IMRX) Interest & Investment Income (2020 - 2026) Analysis & Trends
Immuneering's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 210.23% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $4.0 million (up 77.88% YoY), while the FY2025 annual figure was $3.0 million, up 17.2% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.4 million, down from $1.9 million in the prior quarter.
- The five-year high for Interest & Investment Income was $1.9 million in Q4 2025, with the low at $132506.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $547072.0 (2024), against an average of $683209.8.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 4281.68% in 2022, then tumbled 60.78% in 2025.
- Immuneering's Interest & Investment Income stood at $516168.0 in 2022, then jumped by 46.1% to $754144.0 in 2023, then sank by 44.94% to $415240.0 in 2024, then surged by 348.19% to $1.9 million in 2025, then dropped by 26.9% to $1.4 million in 2026.
- Business Quant data shows IMRX's Interest & Investment Income at $1.4 million in Q1 2026, $1.9 million in Q4 2025, and $415831.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Immuneering | 344.51 Mn | 344.51 Mn | - | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 415,831.00 |
| Jun 30, 2025 | 324,013.00 |
| Mar 31, 2025 | 438,520.00 |
| Dec 31, 2024 | 415,240.00 |
| Sep 30, 2024 | 547,072.00 |
| Jun 30, 2024 | 826,104.00 |
| Mar 31, 2024 | 804,884.00 |
| Dec 31, 2023 | 754,144.00 |
| Sep 30, 2023 | 855,532.00 |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 831,274.00 |
| Dec 31, 2022 | 516,168.00 |
| Sep 30, 2022 | 222,985.00 |
| Jun 30, 2022 | 142,799.00 |
| Mar 31, 2022 | 132,506.00 |
| Dec 31, 2021 | 142,885.00 |
| Sep 30, 2021 | 17,400.00 |